Evidence map›Paper›PMID 40145722›Full record

ArticleClinical pharmacology in drug development2025

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein Inhibition.

Hongxia Jia, T Eric Ballard, Liming Zhang, Lawrence Cohen, Mackenzie C Bergagnini-Kolev, Ian E Templeton, Hannah M Jones, Wei Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongxia JiaTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.
T Eric BallardTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Liming ZhangTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Lawrence CohenTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Mackenzie C Bergagnini-KolevSimcyp Division, Certara UK Ltd, Sheffield, UK.
Ian E TempletonSimcyp Division, Certara UK Ltd, Sheffield, UK.
Hannah M JonesSimcyp Division, Certara UK Ltd, Sheffield, UK.
Wei YinTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soticlestat (TAK-935) is a cholesterol 24-hydroxylase inhibitor. A physiologically-based pharmacokinetic model has been developed to predict potential soticlestat drug-drug interactions (DDIs) using the Simcyp v20 Population-based Simulator and verified with data from single-/multiple-rising-dose and clinical DDI studies. Simulated area under the plasma concentration-time curve from 0 to infinity (AUC

Indexed as

ATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 Enzyme InhibitorsModels, BiologicalAdultArea Under CurveComputer SimulationCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsDrug InteractionsFemaleHumansItraconazoleMaleMiddle AgedYoung AdultATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsCytochrome P-450 Enzyme InhibitorsItraconazolecytochrome P450drug–drug interactionsP‐glycoproteinphysiologically based pharmacokinetic modelingsoticlestat

Identifiers

PMID40145722
PMCPMC12044326

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.